Marks Group Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.95M Buy
2,123
+264
+14% +$268K 0.19% 134
2025
Q4
$2M Buy
1,859
+1,399
+304% +$1.34M 0.19% 129
2025
Q3
$351K Buy
460
+5
+1% +$3.72K 0.03% 249
2025
Q2
$354K Sell
455
-76
-14% -$59.1K 0.03% 253
2025
Q1
$438K Hold
531
0.04% 250
2024
Q4
$410K Hold
531
0.04% 238
2024
Q3
$470K Sell
531
-21
-4% -$18.9K 0.04% 227
2024
Q2
$500K Hold
552
0.05% 222
2024
Q1
$430K Sell
552
-60
-10% -$42.7K 0.04% 230
2023
Q4
$357K Buy
612
+137
+29% +$80K 0.04% 239
2023
Q3
$255K Hold
475
0.03% 256
2023
Q2
$223K Buy
+475
New +$199K 0.03% 267
2023
Q1
Sell
-636
Closed -$233K 285
2022
Q4
$233K Hold
636
0.03% 257
2022
Q3
$206K Hold
636
0.03% 261
2022
Q2
$206K Buy
+636
New +$191K 0.03% 279

Other funds holding LLY

Marks Group Wealth Management's LLY Position: Q1 2026 in Review

Marks Group Wealth Management increased its Eli Lilly (LLY) stake by 14% in Q1 2026, buying an estimated $268K and bringing the position to 2,123 shares worth $1.95M. The position accounts for 0.19% of the portfolio, ranked #134.

Marks Group Wealth Management first reported a position in LLY in Q2 2022 and has held it in 15 quarters since. The position peaked at $2M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Marks Group Wealth Management held 2,123 shares of Eli Lilly worth $1.95M as of Q1 2026.
  • Marks Group Wealth Management bought 264 Eli Lilly shares in Q1 2026, an estimated $268K.
  • Eli Lilly made up 0.19% of Marks Group Wealth Management's portfolio in Q1 2026, its #134 holding.
  • Marks Group Wealth Management first reported a position in Eli Lilly in Q2 2022 and has held it in 15 quarters since.
  • Marks Group Wealth Management's Eli Lilly position peaked at $2M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Marks Group Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.